Understanding the Activity of Antibiotics in Cerebrospinal Fluid in vitro

Pharmacology

Volumn 97, Issue 5-6, 2016, Pages 233-244

  Matzneller, Peter ^a   Burian, Angela ^a   Zeitlinger, Markus ^a   Sauermann, Robert ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Main Assoc of Austrian Social Security Institutions   (Austria)

Author keywords

Antibiotics; Cerebrospinal fluid; In vitro; Infection

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; FOSFOMYCIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; BRAIN VENTRICULITIS; CEREBROSPINAL FLUID; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENINGITIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CEREBROSPINAL FLUID; HUMANS;

EID: 84958787229     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000444263     Document Type: Review

References (54)

1. Friedland IR, et al: Evaluation of antimicrobial regimens for treatment of experimental penicillin-And cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37: 1630-1636.
2. McCracken GH Jr, Sakata Y: Antimicrobial therapy of experimental meningitis caused by Streptococcus pneumoniae strains with different susceptibilities to penicillin. Antimicrob Agents Chemother 1985; 27: 141-145.
3. Täuber MG, et al: New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1985; 27: 340-342.
4. Nau R, et al: Activity of fosfomycin in a rabbit model of experimental pneumococcal meningitis. J Antimicrob Chemother 1995; 36: 997-1004.
5. Nau R, et al: Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1995; 39: 593-597.
6. Lutsar I, McCracken GH Jr, Friedland IR: Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117-1127; quiz 1128-1129.
7. Segal MB: Extracellular and cerebrospinal fluids. J Inherit Metab Dis 1993; 16: 617-638.
8. Kandel ER, Schwartz JH, Jessell TM: Principles of Neural Science, ed 4. McGraw-Hill, 2000.
9. Hasbun R: Cerebrospinal fluid in central nervous system infections; in Scheld WM, Whitley RJ, Marra CM (eds): Infections of the Central Nervous System. Philadelphia, Wolters Kluwer Health, 2014.
10. Scheld WM, et al: Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone. J Clin Invest 1980; 66: 243-253.
11. Nau R, Sörgel F, Prange HW: Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998; 35: 223-246.
12. Cunniffe JG, Whitby-Strevens S, Wilcox MH: Effect of pH changes in cerebrospinal fluid specimens on bacterial survival and antigen test results. J Clin Pathol 1996; 49: 249-253.
13. Sauermann R, et al: Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro. J Antimicrob Chemother 2008; 62: 1057-1060.
14. Pfausler B, et al: Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-Associated ventriculitis. J Antimicrob Chemother 2004; 53: 848-852.
15. Köhnen E, Pfeifer G, Frenkel C: Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection 1987; 15: 422-424.
16. Brunner M, et al: Penetration of fosfomycin into the parenchyma of human brain: A case study in three patients. Br J Clin Pharmacol 2002; 54: 548-550.
17. Pfeifer G, Frenkel C, Entzian W: Pharmacokinetic aspects of cerebrospinal fluid penetration of fosfomycin. Int J Clin Pharmacol Res 1985; 5: 171-174.
18. Sauermann R, et al: Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemother 2009; 64: 821-823.
19. Ribes S, et al: Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporinresistant Streptococcus pneumoniae. J Antimicrob Chemother 2006; 57: 931-936.
20. Dette GA, et al: Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues. J Antimicrob Chemother 1983; 11: 517-524.
21. Ellington MJ, et al: Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother 2006; 58: 848-852.
22. Souli M, et al: In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011; 55: 2395-2397.
23. Wehrli W: Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983; 5(suppl 3):S407-S411.
24. van Ingen J, et al: Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 2011; 52:e194-e199.
25. Nau R, et al: Rifampin for therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1994; 38: 1186-1189.
26. Ribes S, et al: Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916. J Antimicrob Chemother 2005; 56: 979-982.
27. Eagle H, Musselman AD: The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88: 99-131.
28. Ambrose PG, et al: Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002; 49: 445-453.
29. Cottagnoud P, et al: Cefepime is efficacious against penicillin-And quinolone-resistant pneumococci in experimental meningitis. J Antimicrob Chemother 2002; 49: 327-330.
30. Gerber CM, et al: Evaluation of cefepime alone and in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. J Antimicrob Chemother 2000; 45: 63-68.
31. Turnidge JD: Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Diagn Microbiol Infect Dis 1995; 22: 57-69.
32. Zhanel GG, et al: Effect of pooled human cerebrospinal fluid on the postantibiotic effects of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli. Antimicrob Agents Chemother 1992; 36: 1136-1139.
33. Karlowsky JA, et al: In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth. Antimicrob Agents Chemother 1993; 37: 1154-1157.
34. Köhn F, et al: Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob Agents Chemother 2003; 47: 2487-2491.
35. Kim KS: Comparison of cefotaxime, imipenem-cilastatin, ampicillin-gentamicin, and ampicillin-chloramphenicol in the treatment of experimental Escherichia coli bacteremia and meningitis. Antimicrob Agents Chemother 1985; 28: 433-436.
36. Friedland IR, Klugman KP: Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with highdosage cefotaxime. Antimicrob Agents Chemother 1997; 41: 1888-1891.
37. Seddon M, et al: Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother 1980; 18: 240-242.
38. Stoeckel K, et al: Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 1981; 29: 650-657.
39. Ravizzola G, et al: Ceftriaxone against gramnegative and gram-positive bacteria: bactericidal and post-Antibiotic effect. Chemioterapia 1985; 4: 204-208.
40. Buxbaum A, Georgopoulos A: Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. Infection 1996; 24: 459-464.
41. Aldridge KE: Comparison of the post-Antibiotic effect (PAE) induced by ceftizoxime, ceftriaxone, cefoxitin, ampicillin-sulbactam, and ticarcillin-clavulanate against selected isolates of Bacteroides fragilis and B. Thetaiotaomicron. Anaerobe 2002; 8: 295-299.
42. Decazes JM, Ernst JD, Sande MA: Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis. Antimicrob Agents Chemother 1983; 24: 463-467.
43. Gerber J, et al: Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother 2003; 47: 1313-1317.
44. Grandgirard D, et al: Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2010; 54: 1323-1326.
45. Wolfson JS, Hooper DC: The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28: 581-586.
46. Odenholt I, Löwdin E, Cars O: Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin. Antimicrob Agents Chemother 2003; 47: 3352-3356.
47. Kumar A, et al: Post-Antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia. J Antimicrob Chemother 1992; 30: 597-602.
48. Fuursted K: Post-Antibiotic effect of ciprofloxacin on Pseudomonas aeruginosa. Eur J Clin Microbiol 1987; 6: 271-274.
49. Scheld WM: Quinolone therapy for infections of the central nervous system. Rev Infect Dis 1989; 11(suppl 5):S1194-S1202.
50. Freeman CD, et al: Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-686.
51. Cottagnoud P, et al: Gentamicin increases the efficacy of vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model. Antimicrob Agents Chemother 2002; 46: 188-190.
52. Scheld WM, Brown RS Jr, Sande MA: Comparison of netilmicin with gentamicin in the therapy of experimental Escherichia coli meningitis. Antimicrob Agents Chemother 1978; 13: 899-904.
53. Nagarajan R: Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother 1991; 35: 605-609.
54. Nagl M, et al: Bactericidal activity of vancomycin in cerebrospinal fluid. Antimicrob Agents Chemother 1999; 43: 1932-1934.